A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients
Jie Qiao, Yunshan Zhang, Xiaoyan Liang, Tuong Ho, Hong-Yuan Huang, Sung-Hoon Kim, Marie Goethberg, Bernadette Mannaerts, Joan-Carles Arce, Jie Qiao, Yunshan Zhang, Xiaoyan Liang, Tuong Ho, Hong-Yuan Huang, Sung-Hoon Kim, Marie Goethberg, Bernadette Mannaerts, Joan-Carles Arce
Abstract
Study question: Is ovarian stimulation with follitropin delta in its individualised fixed-dose regimen at least as efficacious as follitropin alfa in a conventional dosing regimen in Asian population?
Summary answer: Ovarian stimulation with individualised follitropin delta dosing resulted in a non-inferior ongoing pregnancy rate, a significantly higher live birth rate and a significantly lower incidence of early ovarian hyperstimulation syndrome (OHSS) and/or preventive interventions compared to conventional follitropin alfa dosing.
What is known already: Previous randomised controlled trials conducted in Japan as well as in Europe, North- and South America have demonstrated that ovarian stimulation with the individualised follitropin delta dosing regimen based on serum anti-Müllerian hormone (AMH) level and body weight modulated the ovarian response and reduced the risk of OHSS without compromising pregnancy and live birth rates.
Study design, size, duration: Randomised, controlled, multi-centre, assessor-blind trial conducted in 1009 Asian patients from mainland China, South Korea, Vietnam and Taiwan, undergoing their first IVF/ICSI cycle. Randomisation was stratified by age (<35, 35-37, 38-40 years). The primary endpoint was ongoing pregnancy rate assessed 10-11 weeks after embryo transfer in the fresh cycle (non-inferiority limit -10.0%; analysis adjusted for age stratum).
Participants/materials, setting, methods: The follitropin delta treatment consisted of a fixed daily dose individualised according to each patient's initial AMH level and body weight (AMH <15 pmol/l: 12 μg; AMH ≥15 pmol/l: 0.19 to 0.10 μg/kg; min-max 6-12 μg). The follitropin alfa dose was 150 IU/day for the first 5 days with subsequent potential dose adjustments according to individual response. A GnRH antagonist protocol was applied. OHSS was classified based on Golan's system. Women with an ongoing pregnancy were followed until live birth and 4 weeks after.
Main results and the role of chance: The number of oocytes retrieved was significantly (P < 0.001) lower with individualised follitropin delta versus conventional follitropin alfa (10.0 ± 6.1 versus 12.4 ± 7.3). Nevertheless, compared to the conventional dosing approach, the individualised follitropin delta dosing regimen resulted in on average 2 more oocytes (9.6 ± 5.3 versus 7.6 ± 3.5) in potential low responders as indicated by AMH <15 pmol/l, and on average 3 fewer oocytes (10.1 ± 6.3 versus 13.8 ± 7.5) in potential high responders as indicated by AMH ≥15 pmol/l. Among women with AMH ≥15 pmol/l, excessive response occurred less frequently with individualised follitropin delta than with follitropin alfa (≥15 oocytes: 20.2% versus 39.1%; ≥20 oocytes: 6.7% versus 18.5%; both P < 0.001). The incidence of early OHSS and/or preventive interventions for early OHSS was significantly (P = 0.004) reduced from 9.6% with follitropin alfa to 5.0% with individualised follitropin delta. The total gonadotropin use was significantly (P < 0.001) reduced from an average of 109.9 ± 32.9 μg (1498 ± 448 IU) follitropin alfa to 77.5 ± 24.4 μg follitropin delta. Non-inferiority of follitropin delta in its individualised dosing regimen to conventional follitropin alfa was established with respect to the primary endpoint of ongoing pregnancy rate which was 31.3% with follitropin delta compared to 25.7% with follitropin alfa (estimated mean difference 5.4% [95% CI: -0.2%; 11.0%]). The live birth rate was significantly higher at 31.3% with individualised follitropin delta compared to 24.7% with follitropin alfa (estimated mean difference 6.4% [95% CI: 0.9%; 11.9%]; P = 0.023). The live birth rate for each stratum were as follows for follitropin delta and follitropin alfa, respectively; <35 years: 31.0% versus 25.0%, 35-37 years: 35.3% versus 26.7%, 38-40 years: 20.0% versus 14.3%.
Limitations, reasons for caution: The trial only covered the clinical outcome of one treatment cycle with fresh cleavage-stage embryo transfers.
Wider implications of the findings: The present trial shows that in addition to reducing the early OHSS risk, follitropin delta in its individualised fixed-dose regimen has the potential to improve the success rate in fresh cycles across all ages and with a lower gonadotropin consumption compared to conventional follitropin alfa dosing.
Study funding/competing interest(s): This study was funded by Ferring Pharmaceuticals. J.Q., Y.Z., X.L., T.H., H.-Y.H. and S.-H.K. have received institutional (not personal) clinical trial fees from Ferring Pharmaceuticals. M.G., B.M. and J.-C.A. are employees of Ferring Pharmaceuticals. J.-C.A. has pending and issued patent applications in the WO 2013/020996 and WO 2019/043143 patent families that comprise allowed and granted patent rights related to follitropin delta.
Trial registration number: NCT03296527 (clinicaltrials.gov).
Trial registration date: 28 September 2017.
Date of first patient’s enrolment: 1 December 2017.
Keywords: anti-Müllerian hormone; follitropin delta; individualised dosing; live birth; ovarian stimulation.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.
Figures
References
- Arce J-C, Klein BM, Erichsen L.. Using AMH for determining a stratified gonadotropin dosing regimen for IVF/ICSI and optimizing outcomes. In: Seifer DB, Tal R (eds). Anti-Müllerian Hormone: Biology, Role in Ovarian Function and Clinical Significance. Hauppauge, NY: Nova Science Publishers, Inc, 2016, 83–102.
- Bleil ME, Gregorich SE, Adler NE, Sternfeld B, Rosen MP, Cedars MI.. Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling women. Fertil Steril 2014;101:199–207.
- Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, Arce J-C; ESTHER-2 Study Group. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online 2019;38:195–205.
- Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Jenkins J, Pellicer A.. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod 2010;25:2092–2100.
- Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM.. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update 2014;20:688–701.
- Deurenberg P, Deurenberg-Yap M, Guricci S.. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 2002;3:141–146.
- European Medicines Agency. Gonal-f. Summary of Product Characteristics. 2021. (15 March 2021, date last accessed).
- Fauser BCJM, Diedrich K, Devroey P; Evian Annual Reproduction Workshop Group 2007. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 2008;14:1–14.
- Fleming R, Broekmans F, Calhaz-Jorge C, Dracea L, Alexander H, Nyboe Andersen A, Blockeel C, Jenkins J, Lunenfeld B, Platteau P. et al.Can anti-Müllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation? Reprod Biomed Online 2013;26:431–439.
- Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E.. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430–440.
- Ishihara O, Arce J-C; Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online 2021;42:909–914.
- La Marca A, Sunkara SK.. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014;20:124–140.
- Nelson SM, Aijun S, Ling Q, Tengda X, Wei X, Yan D, Yanfang W, Zenghui T, Xinqi C, Fraser A. et al.Ethnic discordance in serum anti-Müllerian hormone in healthy women: a population study from China and Europe. Reprod Biomed Online 2020;40:461–467.
- Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, Ambrose P, Fleming R.. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867–875.
- Nelson SM.Biomarkers of ovarian response: current and future applications. Fertil Steril 2013;99:963–969.
- Nyboe Andersen A, Nelson SM, Fauser BCJM, García-Velasco JA, Klein BM, Arce J-C; ESTHER-1 Study Group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril 2017;107:387–396.
- Sterrenburg MD, Veltman-Verhulst SM, Eijkemans MJC, Hughes EG, Macklon NS, Broekmans FJ, Fauser BCJM.. Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. Hum Reprod Update 2011;17:184–196.
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157–163.
Source: PubMed